Sentinel Lymph Node Biopsy in Early Breast Cancer

Area of Science:

• Oncology
• Surgical Oncology
• Breast Cancer Research

Background:

• Axillary surgery for breast cancer is evolving, with sentinel lymph node biopsy (SLNB) largely replacing axillary dissection (ALD) for staging.
• The scope of SLNB indications has expanded, and its role in specific patient subgroups (e.g., multicentric disease, large tumors) is under discussion.
• While ALD is now primarily for node-positive patients, its therapeutic value is increasingly questioned, alongside its diagnostic utility.

Purpose of the Study:

• To review current standards in axillary surgery for primary breast cancer.
• To discuss the evolving diagnostic and therapeutic roles of SLNB and ALD.
• To address open questions regarding axillary staging and treatment planning in early breast cancer.

Main Methods:

• Review of current surgical practices in axillary staging for breast cancer.
• Analysis of the expanding indications and implications of SLNB.
• Discussion of the diminishing role and questioned value of ALD in contemporary breast cancer treatment.

Main Results:

• SLNB has become the standard staging procedure, largely replacing ALD.
• The indications for SLNB are expanding, with ongoing debate regarding its application in specific patient populations and its impact on treatment decisions.
• The therapeutic and diagnostic value of completion ALD in node-positive patients is being critically re-evaluated.

Conclusions:

• Axillary surgery for breast cancer is transitioning towards less invasive staging with SLNB.
• Further research is needed to clarify the optimal role of SLNB and the remaining indications for ALD.
• Current standards emphasize minimizing axillary dissection in node-negative patients while reassessing the benefits of ALD in node-positive cases.